Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Realizing the potential of agonistic antibody immunotherapy.

Nature reviews. Drug discovery·2026
Same author

PD-1 signaling and PD-1 blockade-mediated tumor control are established at microvillar T cell contacts.

Science immunology·2026
Same author

Enzymatic Remodelling of Tumour Microenvironment Enhances Anti-CEACAM5 CAR T-Cell Efficacy Against Colorectal Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis.

Science advances·2025
Same author

The Structural Biology of T-Cell Antigen Detection at Close Contacts.

Immunological reviews·2025

Related Experiment Video

Updated: Jun 17, 2026

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery
05:15

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Published on: September 27, 2021

1.4K

Combination CD200R/PD-1 blockade in a humanised mouse model.

Martin Fellermeyer1,2, Consuelo Anzilotti1,2,3, Christopher Paluch1,2,3

  • 1MRC Human Immunology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Immunotherapy Advances
|April 21, 2023
PubMed
Summary
This summary is machine-generated.

Combination cancer immunotherapy using PD-1 blockade and CD200R antagonism did not improve survival in mouse models. Further research is needed for CD200R-blocking antibodies in specific tumor types.

Keywords:
CD200RPD-1cancer immunotherapymonoclonal antibodynivolumab

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

458

Related Experiment Videos

Last Updated: Jun 17, 2026

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery
05:15

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Published on: September 27, 2021

1.4K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

458

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cancer immunotherapy increasingly utilizes immune-checkpoint inhibitors to reactivate tumor-infiltrating T cells.
  • Tumors often contain abundant myeloid cells, which can play dual roles in tumor progression and suppression.
  • CD200R is an inhibitory immune receptor found on myeloid cells and lymphoid cells.

Purpose of the Study:

  • To investigate the efficacy of combination therapy using a PD-1 blocking antibody (nivolumab) and a CD200R antagonist (OX108).
  • To evaluate this combination therapy in colorectal (MC38) and lung (LLC1) cancer mouse models.

Main Methods:

  • Produced and validated nivolumab as a murine IgG1 antibody.
  • Tested combination therapy in MC38 and LLC1 mouse cancer models.
  • Analyzed overall survival and infiltrating immune cells.

Main Results:

  • No significant improvement in overall survival was observed with combination therapy compared to nivolumab monotherapy in either model.
  • A trend towards more complete responses was noted in the MC38 model, but immune cell infiltration did not explain this.
  • MC38 cells expressed low CD200, while LLC1 cells were CD200-negative.

Conclusions:

  • Combination of PD-1 blockade and CD200R antagonism did not enhance survival in the tested cancer models.
  • Further investigation of CD200R-blocking antibodies in tumors with high CD200 expression may be warranted.